Vera Therapeutics Inc (VERA)
39.52
-1.86
(-4.49%)
USD |
NASDAQ |
Apr 30, 16:00
39.52
0.00 (0.00%)
After-Hours: 19:45
Vera Therapeutics Cash from Financing (TTM): 133.54M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 133.54M |
September 30, 2023 | 129.42M |
June 30, 2023 | 130.03M |
March 31, 2023 | 129.65M |
December 31, 2022 | 101.93M |
September 30, 2022 | 86.14M |
June 30, 2022 | 85.24M |
Date | Value |
---|---|
March 31, 2022 | 134.18M |
December 31, 2021 | 53.88M |
September 30, 2021 | 128.76M |
June 30, 2021 | 128.67M |
March 31, 2021 | 80.30M |
December 31, 2020 | 85.29M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
53.88M
Minimum
Dec 2021
134.18M
Maximum
Mar 2022
108.23M
Average
128.67M
Median
Jun 2021
Cash from Financing (TTM) Benchmarks
Vertex Pharmaceuticals Inc | -562.20M |
Alpine Immune Sciences Inc | 165.12M |
Fate Therapeutics Inc | 0.085M |
Checkpoint Therapeutics Inc | 40.45M |
Mersana Therapeutics Inc | 94.68M |